Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Methotrexate (MTX) plus leflunomide (LEF) demonstrates a relatively good safety profile overall compared with the combination of MTX and sulfasalazine (SSZ) and strategies involving advanced therapies in rheumatoid arthritis (RA), reports a study.

Methotrexate–leflunomide combo safe in rheumatoid arthritis

15 Oct 2021

Anxiety, depression up risk of persistent opioid use in women undergoing hysterectomy

Opioid fills are common among women who have undergone hysterectomy, and those with preoperative anxiety and depression are more prone to persistent use and related complications, according to a study.

Anxiety, depression up risk of persistent opioid use in women undergoing hysterectomy

Original New Drug Application Approvals by US FDA (01-15 October 2021)

New drug applications approved by US FDA as of 01-15 October 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 October 2021)

Baricitinib: A potential treatment for alopecia areata?

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, may help improve hair growth in patients with severe alopecia areata, according to results from the phase III BRAVE-AA1 and BRAVE-AA2 trials.

Baricitinib: A potential treatment for alopecia areata?

14 Oct 2021

Abnormal nighttime BP doubles death risk in diabetes patients

For adults with diabetes, increased blood pressure (BP) at night (reverse dipping) was associated with more than double the risk of death compared with those whose BP dipped as expected at night, according to the longitudinal CHAMP1ON study presented at Hypertension 2021.

Abnormal nighttime BP doubles death risk in diabetes patients

Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response

A recent study has shown modest drug survival and primary response of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients with rheumatoid arthritis (RA) switching due to failure of a nontumour necrosis factor inhibitor (non-TNFi) bDMARD as the first agent.

Second bDMARD after failure of non-TNFi biologic in RA shows modest drug survival, response

14 Oct 2021

Smoking reduces effect of methotrexate-based treatment in RA patients

Current smoking reduces the response of patients with early rheumatoid arthritis (RA) to methotrexate (MTX) in a dose-responsive manner, regardless of concomitant prednisone use, a recent study has found.

Smoking reduces effect of methotrexate-based treatment in RA patients

14 Oct 2021

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients

14 Oct 2021

Azithromycin not effective against peripartum infection in high-risk, labouring women

A single dose of oral azithromycin with or without amoxicillin falls short of reducing the risk of maternal peripartum or neonatal infection among women experiencing prolonged labour or rupture of membranes at term, a study has found.

Azithromycin not effective against peripartum infection in high-risk, labouring women

Common, cheap osteoporosis drug promising for T2D